# Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

> **NCT05357898** · PHASE1,PHASE2 · TERMINATED · sponsor: **SQZ Biotechnologies** · enrollment: 20 (actual)

## Conditions studied

- Adult Solid Tumor

## Interventions

- **BIOLOGICAL:** SQZ-eAPC-HPV
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT05357898
- **Lead sponsor:** SQZ Biotechnologies
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-03-24
- **Primary completion:** 2023-11-27
- **Final completion:** 2023-11-27
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** Corporate Decision
- **Last updated:** 2024-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05357898

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05357898, "Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05357898. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*